Researchers at the Technical University of Munich (TUM) have developed a novel model system that can be used to precisely track the growth steps and three-dimensional arrangement of pancreatic cancer cells. It also provides ...
Oct 6, 2022
0
69
The incidence rate of clinically significant metachronous colorectal pathology is 32 per 1,000 person-years after index young-onset colorectal cancer (YOCRC), according to a research letter published online Aug. 16 in Gastroenterology.
Sep 27, 2022
0
4
Results of a study led by VHIO investigators and published in Nature Medicine have unmasked mutations in the RNF43 gene as predictive biomarkers of response to treatment with anti-BRAF/EGFR combinatory therapy in patients ...
Sep 27, 2022
0
35
A cohort study of adults undergoing a colonoscopy after a positive fecal immunochemical testing (FIT) result suggest that endoscopists performing colonoscopy in FIT-based screening programs should aim for markedly higher ...
Sep 26, 2022
0
4
A polyp is a small growth of tissue in the colon that can evolve into colorectal cancer. Patients with polyps have a higher risk of evolving cancer in the future.
Sep 26, 2022
0
31
It's been a year since national recommendations issued by the American Cancer Society and the U.S. Multi-Society Task Force called for colorectal cancer (CRC) screening to be lowered to include individuals ages 45 to 49 at ...
Sep 22, 2022
0
49
Last week, actors Ryan Reynolds and Rob McElhenney released a video of themselves getting colonoscopies to encourage others to undergo screening. The procedure detected polyps in the two men, both aged 45.
Sep 21, 2022
0
2
A team led by Ludwig Lausanne's Tatiana Petrova, Jeremiah Bernier-Latmani and alum Christoph Cisarovsky identified a novel mechanism by which stem cells in intestinal tumors generate new blood vessels and evade anti-angiogenic ...
Sep 20, 2022
0
4
Three-quarters of people prefer to do a fecal immunochemical test (FIT) rather than a colonoscopy for their regular colorectal cancer screening, according to a new Cedars-Sinai study.
Sep 13, 2022
0
4
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of ...
Sep 13, 2022
0
20
